Children with IgE-mediated CMPA (immediate cutaneous, gastrointestinal, respiratory, or systemic [anaphylaxis] symptoms; SPT ≥ 3 mm or sIgE > 0.35 kU/L), treated between 2011–2020. This evidence concerns the gene IGHE and anaphylaxis.